Anti-pd -1 monoclonal antibodies have been shown to have anti-tumor activity in the first-line treatment of PD-L1-positive metastatic TNBC and the neoadjuvant treatment of patients with high-risk early TNBC (21, 22). Here, RPL17 is linked to neoplasm.